Pacira Pharma (NASDAQ: PCRX) reported Q1 EPS of $0.02, in-line with the analyst estimate of $0.02. Revenue for the quarter came in at $74.6 million versus the consensus estimate of $73.69 million.

• Pacira reiterated its full year 2018 financial guidance

For earnings history and earnings-related data on Pacira Pharma (PCRX) click here.